Influenzavirus B Infections – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Influenzavirus B Infections – Pipeline Review, H2 2017’, provides an overview of the Influenzavirus B Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenzavirus B Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenzavirus B Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Influenzavirus B Infections

The report reviews pipeline therapeutics for Influenzavirus B Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Influenzavirus B Infections therapeutics and enlists all their major and minor projects

The report assesses Influenzavirus B Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Influenzavirus B Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Influenzavirus B Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Influenzavirus B Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Adimmune Corp

Altravax Inc

Amarillo Biosciences Inc

Aphios Corp

BioCryst Pharmaceuticals Inc

Cadila Healthcare Ltd

ContraFect Corp

Daiichi Sankyo Company Ltd

Fujifilm Holdings Corporation

GlaxoSmithKline Plc

Green Cross Corp

Inovio Pharmaceuticals Inc

Kineta Inc

Medicago Inc

MedImmune LLC

Mucosis BV

Novavax Inc

Park Active Molecules

Romark Laboratories LC

Sanofi

Sanofi Pasteur SA

Shionogi & Co Ltd

SK Chemicals Co Ltd

TSRL Inc

Vaxart Inc

Vectura Group Plc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Influenzavirus B Infections - Overview

Influenzavirus B Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Influenzavirus B Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Influenzavirus B Infections - Companies Involved in Therapeutics Development

AbbVie Inc

Adimmune Corp

Altravax Inc

Amarillo Biosciences Inc

Aphios Corp

BioCryst Pharmaceuticals Inc

Cadila Healthcare Ltd

ContraFect Corp

Daiichi Sankyo Company Ltd

Fujifilm Holdings Corporation

GlaxoSmithKline Plc

Green Cross Corp

Inovio Pharmaceuticals Inc

Kineta Inc

Medicago Inc

MedImmune LLC

Mucosis BV

Novavax Inc

Park Active Molecules

Romark Laboratories LC

Sanofi

Sanofi Pasteur SA

Shionogi & Co Ltd

SK Chemicals Co Ltd

TSRL Inc

Vaxart Inc

Vectura Group Plc

Influenzavirus B Infections - Drug Profiles

AL-18 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APP-0205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APP-309 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-403 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-404 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

favipiravir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fluad (quadrivalent) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GC-3106A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Influenzavirus B Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [serotypes A, B] (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/victoria+ B/yamagata] (quadrivalent, split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KIN-1400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

laninamivir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza A and B Virus Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Influenza B Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NBP-607 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nitazoxanide CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAM-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peramivir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-033188 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VR-736 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VXABYW-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zanamivir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zanamivir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Influenzavirus B Infections - Dormant Projects

Influenzavirus B Infections - Discontinued Products

Influenzavirus B Infections - Product Development Milestones

Featured News & Press Releases

Jul 24, 2017: Shionogi Announces Positive Top-Line Results for S-033188 Phase 3 Study (CAPSTONE-1) in Otherwise Healthy Influenza Patients

Jun 20, 2017: Sanofi Pasteur receives MFDS Approval for VaxigripTetra inj., a New Four-Strain Influenza Vaccine

Mar 06, 2017: TSRL Awarded NIH Grant to Develop Microneedle Patch for Treatment of Influenza

Dec 01, 2016: Secondary Endpoint Data for S-033188, a Novel Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, Support Favorable Primary Endpoint Data Previously Released

Aug 29, 2016: Seqirus receives FDA approval for AFLURIA QUADRIVALENT (Influenza Vaccine) for people 18 years of age and older

Aug 29, 2016: Shionogi Presents Results from a Phase 2 Proof-of-Concept Clinical Trial and Non-Clinical Studies of S-033188, a Novel Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza

Aug 26, 2016: Daiichi Sankyo Receives Additional Dosage Regimen Approval in Japan for Long-acting Neuraminidase Inhibitor Inavir Dry Powder Inhaler 20mg

Aug 25, 2016: VALNEVA Announces Signing of Marketing & Distribution Agreement for Seqirus' Flu vaccine Fluad in Austria

Jun 23, 2016: New Four-Strain Influenza Vaccine, VaxigripTetra, regulatory dossier from Sanofi Pasteur now approved in Europe

Jun 23, 2016: AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season

Feb 12, 2016: Protein Sciences and UNIGEN Reach Agreement to Source Flublok Influenza Vaccine from Japan

Dec 17, 2015: Vaxart Announces Enrollment of First Patient in Influenza B Phase 1 Trial

Jun 04, 2015: Kineta’s Novel Broad Spectrum Antivirals Trigger Effective Natural Immune Response to Flu and Respiratory Virus Infections

May 12, 2015: Kineta Presents Data On Novel Antiviral Compounds Which Inhibit Broad Spectrum of Respiratory Diseases At International Antiviral Conference

Nov 03, 2014: Sanofi Pasteur Announces FDA Approval of Updated Prescribing Information for Fluzone High-Dose Vaccine for Adults 65 and Older

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Influenzavirus B Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Influenzavirus B Infections – Pipeline by AbbVie Inc, H2 2017

Influenzavirus B Infections – Pipeline by Adimmune Corp, H2 2017

Influenzavirus B Infections – Pipeline by Altravax Inc, H2 2017

Influenzavirus B Infections – Pipeline by Amarillo Biosciences Inc, H2 2017

Influenzavirus B Infections – Pipeline by Aphios Corp, H2 2017

Influenzavirus B Infections – Pipeline by BioCryst Pharmaceuticals Inc, H2 2017

Influenzavirus B Infections – Pipeline by Cadila Healthcare Ltd, H2 2017

Influenzavirus B Infections – Pipeline by ContraFect Corp, H2 2017

Influenzavirus B Infections – Pipeline by Daiichi Sankyo Company Ltd, H2 2017

Influenzavirus B Infections – Pipeline by Fujifilm Holdings Corporation, H2 2017

Influenzavirus B Infections – Pipeline by GlaxoSmithKline Plc, H2 2017

Influenzavirus B Infections – Pipeline by Green Cross Corp, H2 2017

Influenzavirus B Infections – Pipeline by Inovio Pharmaceuticals Inc, H2 2017

Influenzavirus B Infections – Pipeline by Kineta Inc, H2 2017

Influenzavirus B Infections – Pipeline by Medicago Inc, H2 2017

Influenzavirus B Infections – Pipeline by MedImmune LLC, H2 2017

Influenzavirus B Infections – Pipeline by Mucosis BV, H2 2017

Influenzavirus B Infections – Pipeline by Novavax Inc, H2 2017

Influenzavirus B Infections – Pipeline by Park Active Molecules, H2 2017

Influenzavirus B Infections – Pipeline by Romark Laboratories LC, H2 2017

Influenzavirus B Infections – Pipeline by Sanofi, H2 2017

Influenzavirus B Infections – Pipeline by Sanofi Pasteur SA, H2 2017

Influenzavirus B Infections – Pipeline by Shionogi & Co Ltd, H2 2017

Influenzavirus B Infections – Pipeline by SK Chemicals Co Ltd, H2 2017

Influenzavirus B Infections – Pipeline by TSRL Inc, H2 2017

Influenzavirus B Infections – Pipeline by Vaxart Inc, H2 2017

Influenzavirus B Infections – Pipeline by Vectura Group Plc, H2 2017

Influenzavirus B Infections – Dormant Projects, H2 2017

Influenzavirus B Infections – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Influenzavirus B Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports